JZL195

C₂₄H₂₃N₃O₅

433.46

MFCD18382122

329825265

NA.77

JZL195 has been used:

• as a selective inhibitor of endocannabinoid (eCB) clearance enzymes to induce in vivo long-term depression at CA3-CA1 synapses and at prelimbic (PrL)-nucleus accumbens (NAc)synapses, to study the neuroprotective action of eCB
• to inhibit the action of hydrolytic enzymes that limit eCB activity, to study the effect of 2-linoleoylglycerol (2-LG) on the human CB1 receptor activity
• as a dual fatty acid amide hydrolase (FAAH)/monoacylglycerol lipase (MAGL) inhibitor to study its dose-related antipruritic effect on the serotonin (5-HT)-induced scratching model

JZL195 is a potent dual inhibitor of Monoacylglycerol lipase (MAGL) and fatty acid amide hydrolase (FAAH), enzymes that degrade the endocannabinoids 2-arachidonoylglycerol (2-AG) and anandamide (AEA), the endogenous ligands for the cannabinoid G-protein coupled receptors CB1 and CB2. IC50 values are 2 nM for MAGL and 4 nM for FAAH. JZL195 has been shown to inhibit endocannabinoid hydrolysis and elevate 2-AG and AEA levels in vivo.

100

≥98% (HPLC)

powder

white to beige

DMSO: ≥5 mg/mL at warmed

−20℃

[O-][N+](=O)c1ccc(OC(=O)N2CCN(CC2)Cc3cccc(Oc4ccccc4)c3)cc1

1S/C24H23N3O5/c28-24(32-22-11-9-20(10-12-22)27(29)30)26-15-13-25(14-16-26)18-19-5-4-8-23(17-19)31-21-6-2-1-3-7-21/h1-12,17H,13-16,18H2

QNYRAEKLMNDRFY-UHFFFAOYSA-N

5, 25 mg in glass bottle

GHS09

Warning

H400

P273

Aquatic Acute 1

11 - Combustible Solids

WGK 3